|
Drugs
on Hire
Over the past few years, authorised generics have flourished,
giving rise to a never-ending debate whether such tactic by
innovator drug companies is fair or lawfully correct. The
dynamics of pharma business have changed with the onset of
authorised generics when the innovator and the generic partner
are subsidiaries of the same pharmaceutical company. Sapna
Dogra explores
Upfront
'Innovation
comes from investments'
John Morris, Global Chair, KPMG, UK talks to Katya Naidu about
the Indian advantage in the global scenario, the trends and
future perspectives.
'It
is an opportunity to showcase expertise'
The International Conference in bioinformatics (InCoB 2006)
is a landmark event organised by the Department of Biotechnology
(DBT) in collaboration with IIT Delhi, JNU and CDAC. Dr T
Madhan Mohan, Advisor DBT and Organising Secretary of InCoB
2006 speaks to Sapna Dogra about this much-awaited event.
Health,
wealth and IPR
Katya Naidu reports on the Second Healthcare and Pharma Summit
organised by the students of the Healthcare Club of the Indian
School of Business (ISB).
What
attracts Private Equity?
The Indian pharma industry has come a long way but why are
investors still thinking twice before investing. Leaving no
doubts that there are indeed many foreign investors who take
interest in investing in the Indian pharma industry, what
is that keeps them back from doing so and how to overcome
the same was talked about at the conference held on Private
Equity and lifesciences in Mumbai.
Alchemist
acquires new technologies
National Botanical Research Institute of India (NBRI) recently
transferred four patented technologies to Alchemist for their
global marketing.
VWR
establishes a subsidiary in Bangalore
VWR International announced the establishment of a full-service,
Wholly Owned Subsidiary (WOS) in Bangalore to cater to the
needs of the pharmaceutical and biotech industry.
IFC
to invest in Ocimum Biosolutions
The Hyderabad-based Ocimum Biosolu-tions announced that International
Finance Corporation (IFC), the private sector arm of the World
Bank Group, will invest $6.5 million of equity, for a minority
stake, and debt in the company.
Signet
: Market Leader - Excipients
Signet Chemical Corporation focuses on speciality pharmaceutical
excipients ever since it was established in 1986.
|
